안구건조증 시장 : 제품 유형, 치료법, 최종 사용자, 유통 채널별 예측(2026-2032년)

The Dry Eye Syndrome Market is projected to grow by USD 8.35 billion at a CAGR of 7.52% by 2032.

Dry Eye Syndrome, also known as dry eye disease, is a chronic, multifactorial ocular surface disorder associated with tear film instability, inflammation, hyperosmolarity, and neurosensory abnormalities, as defined by TFOS DEWS II. The condition affects visual comfort, reading speed, screen tolerance, contact lens wear, post-surgical recovery, workplace productivity, and overall quality of life.

The dry eye syndrome landscape is expanding as aging populations, prolonged digital device use, cataract and refractive surgery volumes, autoimmune diseases, diabetes, contact lens adoption, air pollution, and low-humidity environments increase the burden of evaporative dry eye and aqueous-deficient dry eye. Growth is strongest where diagnosis is shifting from symptom-based care toward objective testing, targeted prescription therapies, lipid-layer support, and device-based management of meibomian gland dysfunction.

Transformative Shifts in the Dry Eye Landscape

The dry eye landscape is moving beyond artificial tears toward mechanism-based treatment pathways. Clinicians increasingly differentiate aqueous-deficient dry eye from evaporative dry eye, particularly meibomian gland dysfunction, using tear osmolarity, inflammatory markers, ocular surface staining, tear breakup time, meibography, and patient-reported outcome tools.

Commercial innovation is concentrated in preservative-free lubricants, anti-inflammatory therapies such as cyclosporine and lifitegrast, neurostimulation approaches, tear conservation, thermal pulsation, intense pulsed light, and lipid-targeted treatments. This shift is raising the value of evidence-backed products that demonstrate durable symptom relief, objective sign improvement, safety in chronic use, and compatibility with digital health-enabled eye care.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative enabler across dry eye screening, diagnosis, clinical workflow, and patient monitoring. AI-supported image analysis can help quantify meibomian gland dropout, lid margin changes, blink patterns, ocular redness, and tear film behavior, while electronic health record analytics can identify high-risk patients based on age, medication exposure, autoimmune disease, diabetes, ocular surgery history, and screen-intensive occupations.

For manufacturers and providers, AI can improve trial design, segment patients by phenotype, support adherence programs, and personalize treatment escalation. Adoption will depend on clinically validated algorithms, transparent performance metrics, bias testing across diverse populations, cybersecurity controls, and alignment with medical device and software-as-a-medical-device regulations.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific represents a high-volume growth arena due to large aging populations, urbanization, high digital device exposure, contact lens use, pollution exposure, and rising access to ophthalmology services in China, Japan, India, South Korea, Australia, and ASEAN markets. North America remains a leading value market, supported by specialist eye care networks, optometry-led diagnosis, prescription therapy adoption, established regulatory pathways, and high patient awareness of chronic ocular surface disease.

Europe benefits from structured clinical practice, strong optometry and ophthalmology access, and regulatory emphasis on product safety, although pricing and reimbursement vary across countries. Latin America is expanding through private eye care, retail pharmacy access, and improving awareness in Brazil and Mexico. The Middle East faces elevated dry eye risk from arid climates, air conditioning, dust exposure, and screen use, while Africa remains underdiagnosed, with growth tied to access, affordability, professional training, and distribution expansion.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are gaining momentum as urban eye care infrastructure, medical tourism, rising contact lens use, and digital lifestyles increase diagnosis and demand for lubricants, diagnostics, and office-based procedures. GCC countries show strong need for dry eye management because hot, dry climates, indoor air conditioning, high screen exposure, and premium healthcare investment create a favorable environment for advanced diagnostics and prescription products.

The European Union provides a harmonized regulatory foundation for medical products, although market access and reimbursement decisions remain country-specific. BRICS countries offer scale, local manufacturing opportunities, and expanding middle-class demand, while the G7 continues to lead in clinical research, premium therapeutics, diagnostic adoption, and evidence-based reimbursement. NATO markets are relevant for operational vision readiness, defense healthcare systems, and resilient medical supply chains across allied countries.

Key Country Insights Across Major Dry Eye Markets

The United States leads in prescription dry eye innovation, clinical trials, device adoption, and consumer awareness, while Canada shows steady demand through optometry-led care and access to preservative-free products. Mexico and Brazil are important Latin American markets where private ophthalmology, retail pharmacy channels, urbanization, and rising chronic disease prevalence support growth. In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established eye care systems, aging demographics, and structured clinical pathways, while Russia presents demand shaped by local access, pricing, regulatory requirements, and supply conditions.

China and India offer major long-term volume potential because of population scale, digital lifestyles, pollution exposure, diabetes prevalence, and expanding specialist care. Japan and South Korea are sophisticated markets with high screen use, aging demographics, contact lens penetration, and strong ophthalmology adoption. Australia shows demand linked to aging, outdoor exposure, allergy burden, dry climate zones, and advanced optometry networks.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated portfolios that address both evaporative and aqueous-deficient dry eye, including preservative-free formulations, anti-inflammatory drugs, lipid-layer products, and device-enabled therapies for meibomian gland dysfunction. Evidence generation should include real-world outcomes, patient-reported improvement, objective sign changes, safety in chronic use, and comparative value versus standard care.

Organizations can accelerate growth by investing in clinician education, AI-enabled diagnostics, omnichannel patient engagement, and region-specific access strategies. Partnerships with ophthalmologists, optometrists, pharmacies, digital health platforms, and payers can improve diagnosis, adherence, and treatment continuity while strengthening credibility in a crowded dry eye market.

Research Methodology

This executive summary is built on validated secondary research and market intelligence synthesis, including clinical definitions from TFOS DEWS II, peer-reviewed dry eye epidemiology, regulatory frameworks, product approvals, treatment guidelines, healthcare infrastructure indicators, and regional access patterns. Insights were cross-checked to avoid unsupported claims and to reflect current clinical and commercial realities.

The methodology combines disease-burden assessment, segmentation by treatment modality and care pathway, regional demand mapping, technology trend analysis, and competitive landscape review. Qualitative interpretation was used only where supported by documented clinical practice, regulatory evidence, or observable market behavior, while avoiding market sizing, market share, and forecasting assumptions.

Conclusion

Dry Eye Syndrome is evolving from an often underrecognized discomfort condition into a clinically managed chronic ocular surface disease with strong demand for targeted, measurable, and long-term solutions. Growth is supported by aging, digitalization, environmental stressors, ocular procedures, chronic inflammatory conditions, and better diagnostic tools.

The strongest opportunities will favor organizations that combine science-backed therapies, objective diagnostics, AI-enabled personalization, clinician education, and locally relevant access models. As care becomes more phenotype-driven, the dry eye syndrome landscape is positioned for sustained innovation across pharmaceuticals, devices, diagnostics, and digital eye health.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Dry Eye Syndrome Market, by Product Type

• 7.1. Devices
• 7.2. Eye Drops
• 7.3. Eye Gels
• 7.4. Eye Ointments
• 7.5. Punctal Plugs

8. Dry Eye Syndrome Market, by Treatment Type

• 8.1. Artificial Tears
• 8.2. Medical Devices
• 8.3. Nutraceuticals
• 8.4. Prescription Drug Therapy
  • 8.4.1. Corticosteroids
  • 8.4.2. Cyclosporine
  • 8.4.3. Lifitegrast

9. Dry Eye Syndrome Market, by End User

• 9.1. Clinics
• 9.2. Home Care
• 9.3. Hospitals

10. Dry Eye Syndrome Market, by Distribution Channel

• 10.1. Hospital Pharmacy
• 10.2. Online Pharmacy
• 10.3. Retail Pharmacy

11. Dry Eye Syndrome Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Dry Eye Syndrome Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Dry Eye Syndrome Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. AbbVie Inc.
• 15.2. AFT Pharmaceuticals Ltd.
• 15.3. Akorn Operating Company LLC
• 15.4. Alcon Inc.
• 15.5. Bausch + Lomb Corporation
• 15.6. Johnson & Johnson Services, Inc.
• 15.7. Kala Pharmaceuticals, Inc.
• 15.8. Mitotech S.A.
• 15.9. Novaliq GmbH
• 15.10. Novartis AG
• 15.11. OASIS Medical, Inc.
• 15.12. Otsuka Pharmaceutical Co., Ltd.
• 15.13. Rohto Pharmaceutical Co., Ltd.
• 15.14. Santen Pharmaceutical Co., Ltd.
• 15.15. Senju Pharmaceutical Co., Ltd.
• 15.16. Similasan Corporation
• 15.17. Sun Pharmaceutical Industries Ltd.
• 15.18. Thea Pharmaceuticals Ltd.
• 15.19. United Laboratories Co., Ltd.
• 15.20. Ursapharm Arzneimittel GmbH
• 15.21. Zhejiang Jianfeng Group Co., Ltd.